Travere misses primary endpoint in PhIII for rare kidney disease but the company is still considering a 'path forward'

Katherine Lewin

News Reporter

Travere Therapeutics’ drug sparsentan didn’t hit the primary endpoint in a Phase III study in a rare kidney disease, but neither the company nor analysts …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Travere misses primary endpoint in PhIII for rare kidney disease but the company is still considering a 'path forward'

Katherine Lewin

News Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Boehringer’s updated results in HER2-mutated lung cancer impress

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Tra­vere miss­es pri­ma­ry end­point in PhI­II for rare kid­ney dis­ease but the com­pa­ny is still con­sid­er­ing a 'path for­ward'

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Travere misses primary endpoint in PhIII for rare kidney disease but the company is still considering a 'path forward'